United States· US:66302-014_27169364-7492-47e7-b2f5-7dc7d20e36a7
Unituxin
A medicinal product containing dinutuximab, registered in United States by United Therapeutics Corporation.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DINUTUXIMAB
- Manufacturer
- United Therapeutics Corporation
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1166302-014-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dinutuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandQarzibaAbacus Medicine A/S
- BelgiumQarziba 4.5 mg/mlRecordati Netherlands
- SwitzerlandQarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer InfusionslösungMedius AG
- CzechiaQARZIBARecordati Netherlands B.V., Schiphol-Rijk
- SpainQARZIBA 4,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- FranceQARZIBA 4,5 mg/ml, solution à diluer pour perfusionRECORDATI IRELAND
- United KingdomQarziba 20mg/4.5ml concentrate for solution for infusion vialsRecordati UK Ltd
- IrelandQarziba 4.5 mg/mL concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qarziba
- Liechtenstein · Qarziba
- Norway · Qarziba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/071d39a0-9d7c-4e9a-bfbc-bfb924157fc7 GET /v1/drugs/071d39a0-9d7c-4e9a-bfbc-bfb924157fc7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "3.5",
"substance": "DINUTUXIMAB",
"productndc": "66302-014",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125516",
"marketing_category": "BLA"
}See everything about dinutuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.